logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10731181 B1

PDFFull Text
Date of Patent:
Aug. 04, 2020

Filed:

Jun. 21, 2016

Crispr-based genome modification and regulation

Applicant:

Sigma-aldrich Co. Llc, St. Louis, MO (US);

Inventors:

Fuqiang Chen, St. Louis, MO (US);

Gregory D. Davis, St. Louis, MO (US);

Assignee:

Sigma, Aldrich Co. LLC, St. Louis, MO (US);

Attorneys:

Benjamin J. Sodey

Sigma-Aldrich Co. LLC

Primary Examiner:

Jennifer Dunston

Int. Cl.
CPC ...
C12N 15/90 (2006.01); C12N 9/22 (2006.01); C12N 15/63 (2006.01); C12N 15/85 (2006.01); C12N 15/11 (2006.01); C12N 15/10 (2006.01); C07K 7/06 (2006.01); C12N 7/00 (2006.01); C12N 15/67 (2006.01); C12N 15/86 (2006.01); C07K 14/46 (2006.01); C12N 9/96 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); C07K 7/06 (2013.01); C07K 14/463 (2013.01); C12N 7/00 (2013.01); C12N 9/22 (2013.01); C12N 9/96 (2013.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); C12N 15/63 (2013.01); C12N 15/67 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); C12Y 301/00 (2013.01); C12Y 301/21004 (2013.01); A61K 38/00 (2013.01); C07K 2319/09 (2013.01); C07K 2319/10 (2013.01); C07K 2319/81 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3513 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/22 (2013.01); C12N 2800/80 (2013.01);
Abstract

The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.

Find Patent Forward Citations

Loading…